Cancer medicine · 2023
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Castillo Martín I, Ribate Villamón E, Muñoz Calabuig M, Santillana Sanz G, Taboada Such E, Casterá Mora E, Abinzano Calasanz M J, Barranco Irigoyen A, Nieto Collado R, Pampliega Vara M, Blanco M L, de Andrés Álvarez S, de Oteyza Pérez J, Del Castillo Bernal T, Font Granada I, Cayuela Jerez A, Díez-Campelo M, Sánchez Abellán R, Vercet Solano C, Díaz Tormo M, Grupo Español de Síndromes Mielodisplásicos (GESMD)
Аннотация
BACKGROUND: In myelodysplastic neoplasms (MDS), the 20q deletion [del(20q)] is a recurrent chromosomal abnormality that it has a high co-occurrence with U2AF1 mutations. Nevertheless, the prognostic impact of U2AF1 in these MDS patients is uncertain and the possible clinical and/or prognostic differences between the mutation type and the mutational burden are also unknown.
METHODS: Our study analyzes different molecular variables in 100 MDS patients with isolated del(20q).
RESULTS & CONCLUSIONS: We describe the high incidence and negative prognostic impact of U2AF1 mutations and other alterations such as in ASXL1 gene to identify prognostic markers that would benefit patients to receive earlier treatment.
METHODS: Our study analyzes different molecular variables in 100 MDS patients with isolated del(20q).
RESULTS & CONCLUSIONS: We describe the high incidence and negative prognostic impact of U2AF1 mutations and other alterations such as in ASXL1 gene to identify prognostic markers that would benefit patients to receive earlier treatment.